



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



**Evaluation of Efficacy and Safety of
Ombitasvir, Paritaprevir, and Ritonavir plus
Ribavirin Based Therapy for Chronic
Hepatitis C with or without Compensated
Cirrhosis in Haemodialysis Patients**

A Thesis

*Submitted for the Fulfillment of the Requirements for the
Master degree
In Pharmaceutical Sciences
(Clinical Pharmacy)*

By

Mai Mohamed Naguib Abdelmenem

Bsc of Pharmaceutical Sciences (2007)

Major. Pharmacist At Al-Maadi Armed Forces Hospital

**Year
2020**



**Evaluation of Efficacy and Safety of
Ombitasvir, paritaprevir, and ritonavir plus
ribavirin Based Therapy for Chronic
Hepatitis C with or without compensated
cirrhosis in Haemodialysis Patients**

A Thesis

Submitted for the Fulfillment of the Requirements for the

***Master degree
In Pharmaceutical Sciences
(Clinical Pharmacy)***

By

Mai Mohamed Naguib Abdelmenem

Bsc of Pharmaceutical sciences (2007)

Major. Pharmacist At Al-Maadi Armed Forces Hospital

Under Supervision of

Prof. Dr. Nagwa Ali Sabri, PhD

*Professor and Head of Clinical Pharmacy Department,
Faculty of Pharmacy, Ain Shams University*

Prof. Dr. Ashraf Ahmed Abu Bakr, MD

*Head of the Department of Gastroenterology and Hepatology,
Professor at Military Medical Academy*

Dr. Sara Mahmoud Zaki, PhD

*Associate Professor of Clinical Pharmacy
Faculty of Pharmacy, Ain Shams University*

**Year
2020**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

”قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا

إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ

الْعَلِيمُ الْحَكِيمُ“

سورة البقرة الآية ٣٢



Acknowledgments

First, I thank "**Allah**" for granting me the power to accomplish this work.

I would like to express my deepest thanks to **Prof. Dr. Nagwa Ali Sabri**, Professor and Head of Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, for her valuable scientific supervision, constructive advice and continuous guidance throughout the work.

I am also greatly indebted to **Prof. Dr. Ashraf Ahmed Mahmoud Abu Bakr**, Head of the Department of Gastroenterology and Hepatology, Professor at Military Medical Academy, for suggesting the topic of research and for providing continuous scientific supervision and follow up. His valuable time and big effort are greatly appreciated. I also thank him for providing guidance especially throughout the genetics part in this study.

My deepest gratitude and appreciation are expressed to **Dr. Sara Mahmoud Zaki**, Lecturer of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, for her divine support and for kindly supplying the laboratory facilities whenever needed. Her constructive criticism, guided me immensely throughout the work and during the revision of the thesis.

I would also like to thank my dear **colleagues** and to all the **workers** at the Faculty of Pharmacy, Ain Shams University for their help and support during this work. Besides, I would like to thank all the **staff members** at Maadi military hospital, for their help during collection of specimens.

Finally, my deepest everlasting thanks and appreciation are for my beloved **parents** for their continuous support and encouragement throughout my life.

والحمد لله رب العالمين.....

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations.....	v
Abstract	viii
Introduction	1
Review of Literature	5
Hepatitis C Virus Infection	5
Kidney Failure	26
Hepatitis C Virus Infection and Kidney Failure	34
Aim of the Work	48
Patients & Methods	49
Results	56
Discussion	80
Summary & Recommendations.....	88
References	92
Arabic Summary	1

List of Tables

Table No.	Title	Page No.
Table 1:	Direct-acting antivirals used to treat hepatitis C virus infections.....	23
Table 2:	Staging of Chronic Kidney Disease based on Glomerular Filtration Rate	30
Table 3:	Demographic data of patients participated in the study	57
Table 4:	Clinical data of patients participated in the study	58
Table 5:	Ribavirin usage data of patients participated in the study	59
Table 6:	Qurevo usage data of patients participated in the study	61
Table 7:	Baseline laboratory data of patients participated in the study.....	62
Table 8:	Sustained Virological Response after Qurevo therapy (3 and 6 months follow up) of patients participated in the study.....	63
Table 9:	Comparison between cirrhotic and non-cirrhotic patients as regards demographic and clinical data.....	64
Table 10:	Comparison between cirrhotic and non-cirrhotic patients as regards the presence of co-morbidities.....	66
Table 11:	Comparison between cirrhotic and non-cirrhotic patients as regards SVR rates	67
Table 12:	Comparison between cirrhotic and non-cirrhotic patients as regards drug administration data.....	68

List of Tables Cont...

Table No.	Title	Page No.
Table 13:	Comparison between all patients as regards serial laboratory measurements (baseline, during and after Qurevo therapy).....	70
Table 14:	Comparison between all patients as regards serial HCV RNA (PCR) assessments (baseline, during and after Qurevo therapy).....	71
Table 15:	Comparison between cirrhotic (21) and non-cirrhotic (29) patients as regards serial 6 laboratory measurements	72
Table 16:	Comparison between Q-RBV group (38) and Q only group (12) as regards serial 6 laboratory measurements	75
Table 17:	Survival table of Qurevo SVR group (44) and Qurevo resistance group (3).....	77
Table 18:	Mean survival time of Qurevo SVR group (44) and Qurevo resistance group (3).....	78

List of Figures

Fig. No.	Title	Page No.
Figure 1:	Simplified diagram of the structure of the Hepatitis C virus particle.....	12
Figure 2:	Extrahepatic manifestations of chronic HCV infection.....	17
Figure 3:	Chemical structure of Paritaprevir, ritonavir plus ombitasvir.....	24
Figure 4:	Consort flow chart.....	56
Figure 5:	Ribavirin usage data of patients participated in the study.....	60
Figure 6:	Qurevo withdrawal rate of patients participated in the study.....	61
Figure 7:	Sustained Virological response of patients participated in the study.....	63
Figure 8:	Comparison between cirrhotic patients and non-cirrhotic patients regarding Metavir fibrosis score.....	65
Figure 9:	Comparison between cirrhotic patients and non-cirrhotic patients regarding serial Hemoglobin measurements.....	73
Figure 10:	Comparison between cirrhotic patients and non-cirrhotic patients regarding serial AST measurements.....	73
Figure 11:	Comparison between cirrhotic patients and non-cirrhotic patients regarding serial ALT measurements.....	74
Figure 12:	Comparison between cirrhotic patients and non-cirrhotic patients regarding serial Total bilirubin measurements.....	74

List of Figures Cont...

Fig. No.	Title	Page No.
Figure 13:	Comparison between Q-RBV group and Q only group regarding serial TLC measurements.....	76
Figure 14:	Kaplan-Meier survival curve showing increased survival probability starting from 2nd month of Qurevo therapy with high significant difference (Log-rank test P = 0.0001).....	78

List of Abbreviations

Abb.	Full term
2D	Two Direct Acting Antiviral
Ab	Antibody
AFP	Alfa Feto-Protein
AKI	Acute Kidney Injury
ALT	Alanine aminotransferase
ANOVA	Analysis Of Variance
ARF	Acute Renal Failure
AST	Aspartate AmioTransferase
BCRP	Breast Cancer Resistance Protein
BMI	Body Mass Index
C4	Complement 4
CBC	Complete Blood Picture
CD81	Antibody for Flow Cytometry
CKD	Chronic Kidney Disease
CryoVas	Cryoglobulinemia Vasculitis
CYP2C8	Cytochrome P450 C8
CYP3A	Cytochrome P450 3A
DAA	Direct Acting Antiviral Agents
DOPPS	Dialysis Outcomes & Practice Patterns Study
E1 , E2	Envelope glycoproteins
EASL	European Association for the Study of the Liver
ECG	Echo-Cardio-Gram
ELISA	Enzyme-Linked Immune-Sorbent-Assay
ESKD	End Stage Kidney Disease
ESRD	End Stage Renal Disease
EU	European Union

List of Abbreviations

GFR	Glomerular Filtration Rate
GT4	Genotype-4
HBV	Hepatitis B Virus
HCC	HepatoCellular Carcinoma
HCV	Hepatitis C Virus
HD	Hemodialysis
HIV	Human Immunodeficiency Virus
HTN	Hypertension
HVR	Hyper Variable Region
IDU	Injection Drug Use
IFN	Interferon
IgG	Immunoglobulin G
IgM	Immunoglobulin M
INR	International Normalized Ratio
IQR	Inter-Quartile Range
KDOQI	Kidney Disease Outcome Quality Initiative
KIDIGO	Kidney Disease Improving Global Outcome
KT	Kidney Transplant
MedCalc	Medical Calculations
MPGN	Most often GenoType-I
NS	Non-Significant
NS3/NS4A	Non Structural Protein 3/4 A
NSAIDs	Non-Steroidal Anti-Inflammatory Drugs
O/E Ratio	Over/Expected Ratio
OATPB/B3	Organic Anion Transporting Polypeptide 1B1/B3
OBV	Ombitasvir
PCR	Polymerase Chain Reaction
PegIFN	Pegylated Interferon
P-gp	P-Glycoprotein
Pi	Protease Inhibitors
PTV	Paritaprevir